Late-stage drug failures drive toxicology testing market growth


The global ADME toxicology testing market is predicted to generate a revenue of $19.21 billion by 2030, with a growth rate of 10.2%.

Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

The predictions are made by in a new market report entitled ‘ADME Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture, OMICS Tech), By Application (Neurotoxicity, Renal Toxicity), By Method (Cellular Assay, In-Silica), and Segment Forecasts, 2023-2030’.

Since 2017, approximately 43% of ADME toxicology testing has been based on cell culture tech, which has been adopted widely due to advantages like near-natural conditions and accurate results obtained at a cellular level.

These assays are conducted for several types of toxic reactions or systems where toxic reactions might take place. Some of the toxicity tests are systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicities that might result in living tissue.

Advancements in testing methods are likely to speed up the drug discovery process and boost the market growth.

ADME toxicology testing market report highlights:
  • The market is driven by an increasing ratio of late-stage drug failures, resulting in loss of valuable time and investment for drug development. Growth and increasing adoption of OMICS technology is also expected to boost revenue generation in the coming years.
  • North America is the largest market for ADME toxicology testing.
  • The developing regions of Asia Pacific and Latin America are set to grow considerably as many multinational and local players are striving to enter the market.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free